Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention Analysis from the controlled abciximab and device investigation to lower late angioplasty complications (cadillac) trial
Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Negoita M, Lansky AJ, Stone GW. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention Analysis from the controlled abciximab and device investigation to lower late angioplasty complications (cadillac) trial. Journal Of The American College Of Cardiology 2004, 44: 547-553. PMID: 15358018, DOI: 10.1016/j.jacc.2004.03.080.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAnemiaAngioplasty, Balloon, CoronaryAntibodies, MonoclonalBlood Component TransfusionFemaleHematocritHemorrhageHospital MortalityHumansImmunoglobulin Fab FragmentsIncidenceMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPlatelet Aggregation InhibitorsPredictive Value of TestsPrognosisRandomized Controlled Trials as TopicStentsStrokeSurvival AnalysisTreatment OutcomeConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCILate Angioplasty Complications (CADILLAC) trialImpact of anemiaComplications TrialMyocardial infarctionWorld Health Organization criteriaPrimary PCI outcomesBlood product transfusionOne-year mortalityBaseline laboratory valuesPercutaneous coronary interventionPresence of anemiaBaseline anemiaControlled AbciximabHospital mortalityProduct transfusionHemorrhagic complicationsIndex hospitalizationCoronary interventionIndependent predictorsPCI outcomesPrognostic importanceAdverse outcomes